As a pharmaceutical company, we focus on providing solutions to address the unmet medical needs of patients around Libya. We operate in a high-risk business sector – and in an age in which many countries are limiting their healthcare spending. To meet these challenges, we continue to invest in our Libyan core markets, as well as emerging markets in developing and recently industrialized countries. Our diverse portfolio includes branded, generic pharmaceuticals, vaccines, and over-the-counter medicines. To expand our business and achieve long-term growth, we’re partnering on high-potential products that complement our in-house portfolio. We focus our acquisition activities on new products and product candidates, and companies that drive our portfolio in key therapeutic categories. We have a special interest in biotech companies, as well as products and licenses related to the fields of oncology and cardiovascular and metabolic diseases.